Market Overview:
The global drugs for vulvovaginal candidiasis market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of vulvovaginal candidiasis, rising awareness about available treatment options, and growing demand for over-the-counter drugs. Based on type, the global drugs for vulvovaginal candidiasis market is segmented into miconazole, clotrimazole, fluconazole, econazole, and other types. Miconazole is expected to account for the largest share of this market in 2018 owing to its high efficacy and widespread use. Based on application, the global drugs for vulvovaginal candidiasis market is segmented into hospital & clinic and pharmacy segments. The hospital & clinic segment accounted for the majority share of this market in 2017 and is projected to grow at a higher CAGR during the forecast period than the pharmacy segment.
Product Definition:
Drugs for Vulvovaginal Candidiasis are medications that are used to treat or prevent a fungal infection of the vagina called vulvovaginal candidiasis.
Miconazole:
Miconazole is an antifungal medication used in the treatment of vaginal and vulvovaginal candidiasis. It works by killing the fungal cells that are responsible for infection. The drug has a wide spectrum of activity against various fungi, including athlete's foot, ringworm, jock itch, and fungal meningitis.
Clotrimazole:
Clotrimazole is an antifungal medication used to treat vaginal yeast infections. It works by killing the fungal cells that are responsible for causing the infection. The drug has a wide spectrum of activity against various pathogenic fungi, including Candida albicans and Aspergillus flavus.
Application Insights:
The global drugs for vulvovaginal candidiasis market by application is categorized into hospital and clinic, and pharmacy. The hospital and clinic segment dominated the overall industry in terms of revenue in 2017 owing to the high prevalence of VVC across various regions including North America, Europe, Asia Pacific, Latin America etc. Furthermore, increasing awareness about effective treatment methods is anticipated to boost growth during the forecast period.
Pharmacy segment held a significant share in 2018 due to presence of key players focusing on manufacturing generic medicines for different diseases which has led them to gain a competitive edge over other companies producing same type of products globally. For instance Pfizer Inc., one of the major pharmaceutical companies has its office at Mexico where they produce their generic medicines under supervision from FDA (U.S). This helps patients get access to cheaper medicine with lesser quality compared to branded counterparts globally as Pfizer Inc are one among many manufacturers worldwide who produce generics outside U.
Regional Analysis:
North America held the largest market share in 2017 owing to the high prevalence of VVC and increasing healthcare expenditure. The region is expected to maintain its dominance throughout the forecast period due to continuous launch of new products, presence of key manufacturers, and increase in awareness about early diagnosis. Moreover, availability of effective treatment methods for VVC such as miconazole nitrate cream and clotrimazole vaginal gel will also help maintain regional market share.
Asia Pacific is anticipated to be one of the fastest growing regions over the forecast period owing to an increase in disposable income levels coupled with rise in consumer awareness regarding sexually transmitted infections (STIs). In addition, rising incidence rate due to changeable climate conditions will boost growth further.
Growth Factors:
- Increasing incidence of vulvovaginal candidiasis
- Rising awareness about the availability and efficacy of drugs for vulvovaginal candidiasis
- Growing number of clinical studies on drugs for vulvovaginal candidiasis
- Launch of novel and innovative drugs for the treatment of vulvovaginal candidiasis
- increasing prevalence of diabetes mellitus
Scope Of The Report
Report Attributes
Report Details
Report Title
Drugs for Vulvovaginal Candidiasis Market Research Report
By Type
Miconazole, Clotrimazole, Fluconazole, Econazole, Other
By Application
Hospital & Clinic, Pharmacy
By Companies
Bayer, Perrigo, J & J, Pfizer, Bristol-Myers Squibb, Effik, Teva, Sanofi, Cisen Pharmaceutical, Kingyork Group
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Drugs for Vulvovaginal Candidiasis Market Report Segments:
The global Drugs for Vulvovaginal Candidiasis market is segmented on the basis of:
Types
Miconazole, Clotrimazole, Fluconazole, Econazole, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital & Clinic, Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer
- Perrigo
- J & J
- Pfizer
- Bristol-Myers Squibb
- Effik
- Teva
- Sanofi
- Cisen Pharmaceutical
- Kingyork Group
Highlights of The Drugs for Vulvovaginal Candidiasis Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Miconazole
- Clotrimazole
- Fluconazole
- Econazole
- Other
- By Application:
- Hospital & Clinic
- Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Drugs for Vulvovaginal Candidiasis Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one drug that is effective for treating vulvovaginal candidiasis, and different drugs are recommended for different types of the infection. Some common drugs used to treat vulvovaginal candidiasis include fluconazole (Diflucan), itraconazole (Sporanox), and voriconazole (Vfend).
Some of the major players in the drugs for vulvovaginal candidiasis market are Bayer, Perrigo, J & J, Pfizer, Bristol-Myers Squibb, Effik, Teva, Sanofi, Cisen Pharmaceutical, Kingyork Group.
The drugs for vulvovaginal candidiasis market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Drugs for Vulvovaginal Candidiasis Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Drugs for Vulvovaginal Candidiasis Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Drugs for Vulvovaginal Candidiasis Market - Supply Chain
4.5. Global Drugs for Vulvovaginal Candidiasis Market Forecast
4.5.1. Drugs for Vulvovaginal Candidiasis Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Drugs for Vulvovaginal Candidiasis Market Size (000 Units) and Y-o-Y Growth
4.5.3. Drugs for Vulvovaginal Candidiasis Market Absolute $ Opportunity
5. Global Drugs for Vulvovaginal Candidiasis Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Type
5.3.1. Miconazole
5.3.2. Clotrimazole
5.3.3. Fluconazole
5.3.4. Econazole
5.3.5. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Drugs for Vulvovaginal Candidiasis Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Application
6.3.1. Hospital & Clinic
6.3.2. Pharmacy
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Drugs for Vulvovaginal Candidiasis Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Drugs for Vulvovaginal Candidiasis Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Drugs for Vulvovaginal Candidiasis Demand Share Forecast, 2019-2026
9. North America Drugs for Vulvovaginal Candidiasis Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Application
9.4.1. Hospital & Clinic
9.4.2. Pharmacy
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Type
9.7.1. Miconazole
9.7.2. Clotrimazole
9.7.3. Fluconazole
9.7.4. Econazole
9.7.5. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Drugs for Vulvovaginal Candidiasis Demand Share Forecast, 2019-2026
10. Latin America Drugs for Vulvovaginal Candidiasis Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Application
10.4.1. Hospital & Clinic
10.4.2. Pharmacy
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Type
10.7.1. Miconazole
10.7.2. Clotrimazole
10.7.3. Fluconazole
10.7.4. Econazole
10.7.5. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Drugs for Vulvovaginal Candidiasis Demand Share Forecast, 2019-2026
11. Europe Drugs for Vulvovaginal Candidiasis Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Application
11.4.1. Hospital & Clinic
11.4.2. Pharmacy
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Type
11.7.1. Miconazole
11.7.2. Clotrimazole
11.7.3. Fluconazole
11.7.4. Econazole
11.7.5. Other
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Drugs for Vulvovaginal Candidiasis Demand Share, 2019-2026
12. Asia Pacific Drugs for Vulvovaginal Candidiasis Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Application
12.4.1. Hospital & Clinic
12.4.2. Pharmacy
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Type
12.7.1. Miconazole
12.7.2. Clotrimazole
12.7.3. Fluconazole
12.7.4. Econazole
12.7.5. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Drugs for Vulvovaginal Candidiasis Demand Share, 2019-2026
13. Middle East & Africa Drugs for Vulvovaginal Candidiasis Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Application
13.4.1. Hospital & Clinic
13.4.2. Pharmacy
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Drugs for Vulvovaginal Candidiasis Market Size and Volume Forecast by Type
13.7.1. Miconazole
13.7.2. Clotrimazole
13.7.3. Fluconazole
13.7.4. Econazole
13.7.5. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Drugs for Vulvovaginal Candidiasis Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Drugs for Vulvovaginal Candidiasis Market: Market Share Analysis
14.2. Drugs for Vulvovaginal Candidiasis Distributors and Customers
14.3. Drugs for Vulvovaginal Candidiasis Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bayer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Perrigo
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. J & J
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bristol-Myers Squibb
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Effik
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Teva
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Sanofi
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Cisen Pharmaceutical
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Kingyork Group
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
